Chris G. Parsons

Glutamate in CNS disorders as a target for drug development: an update

Chris G. Parsons, Wojciech Danysz, G. Quack · Drug News & Perspectives · 1998 · 447 citations

Life Sciences, Neuroscience, Pharmacology +17

Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo

Chris G. Parsons, G. Quack, I. Bresink et al. · Neuropharmacology · 1995 · 312 citations

Life Sciences, Neuroscience, Pharmacology +10

Patch clamp studies on the kinetics and selectivity of N-methyl-d-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan)

Chris G. Parsons, René Gruner, Jouri Rozental et al. · Neuropharmacology · 1993 · 281 citations

Medicine, Pharmacology, Molecular Pharmacology +12

Neuroprotective and symptomatological action of memantine relevant for alzheimer’s disease — a unified glutamatergic hypothesis on the mechanism of action

Wojciech Danysz, Chris G. Parsons, Hans Jörg Möbius et al. · Neurotoxicity Research · 2000 · 262 citations

Life Sciences, Neuroscience, Pharmacology +17

Memantine Improves Cognition and Reduces Alzheimer’s-Like Neuropathology in Transgenic Mice

Hilda Martínez‐Coria, Kim N. Green, Lauren M. Billings et al. · American Journal Of Pathology · 2009 · 215 citations · Full text

Medicine, Neuroscience, Pharmacology +14